相关实验视频

Updated: Jul 15, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

血管免疫细胞T细胞淋巴瘤的发病和治疗策略的进展

Qingyang Zhang¹, Le Yin¹, Qinqiao Lai¹

¹Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Clinical and experimental medicine

|September 27, 2023

概括

血管免疫原性T细胞淋巴瘤 (AITL) 是一种来自毛囊辅助T细胞的攻击性T细胞癌症. 本综述涵盖了AITL的发病过程,强调了治疗方面的挑战,并探索了新的治疗和免疫治疗策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

血管免疫原性T细胞淋巴瘤 (AITL) 是一种来自毛囊辅助T细胞的侵袭性外围T细胞淋巴瘤.
AITL是由一个复杂的瘤微环境定义的,具有免疫细胞失调和细胞外基质改变.

研究的目的:

为了提供AITL病变的概述.
讨论最近AITL治疗策略的进展.
为AITL.突出潜在的治疗点和新兴免疫疗法.

主要方法:

对分子病理生理学的审查,包括遗传突变和微环境组件.
分析当前的治疗方式及其局限性.
探索新的治疗点和免疫治疗方法.

主要成果:

了解AITL分子病理生理学的进展,包括遗传突变和微环境相互作用.
目前的治疗方法通常涉及组合化疗,但对于复发/耐药病例的预后仍然不佳.
新兴的战略重点是针对性疗法和免疫疗法.

结论:

由于其侵略性和预后不佳,AITL存在重大治疗挑战.
对分子驱动因素和微环境的进一步研究对于开发有效的治疗方法至关重要.
包括免疫疗法在内的新型治疗策略为改善AITL管理提供了希望.

关键词:

血管免疫芽细胞T细胞淋巴瘤病变的发生和发病.治疗策略治疗策略

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...